Authors: Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
20% relative risk reduction in three-component MACE (hazard ratio 0.80)
In a multicenter, double-blind, randomized trial, 17,604 patients 45 years of age or older with preexisting cardiovascular disease and a BMI >= 27 but without diabetes received once-weekly subcutaneous semaglutide (2.4 mg) or placebo. The primary composite cardiovascular endpoint was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Over a mean follow-up of 39.8 months, semaglutide reduced primary endpoint risk by 20% (HR 0.80; 95% CI 0.72-0.90; P<0.001).
The landmark SELECT trial establishing a statistically significant 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients treated with once-weekly semaglutide.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
